retatrutide trial Delivers Significant Hemoglobin A1C Reduction, Weight Loss in Phase 3 Type 2 Diabetes Retatrutide Shows 28.3% Weight Loss

The material news: the March 9, 2026 Hims & Hers-Novo Nordisk partnership gives Hers patients legitimately branded oral Wegovy at $149/mo (intro through August 31, 2026, rising to $199 after)

Many patients blame themselves, even though obesity is a disease of disordered appetite and biological origin, not simply the result of habits or willpower, he said

The evidence base here is predominantly preclinical and anecdotal for fat loss specifically

For those researching long-term peptide strategies, the broader landscape of weight management peptides offers numerous options for sustained metabolic support

Our practice and how to proceed At The Hetrick Center we recognize the rise of GLP-1 therapies and the interest many of our patients have in metabolic optimization, healthy weight, and sustainable nutrition

Patients should maintain adequate fluid intake and seek medical advice if they notice significantly reduced urine output, dizziness on standing, or other signs of dehydration